Axsome Therapeutics (AXSM) cash on hand

Cash · fiscal 2025
$322.93M

Axsome Therapeutics (AXSM) held cash of $322.93M at the end of fiscal 2025 (December 31, 2025). That is 2.4% higher than the $315.35M of fiscal 2024. Figures as of 17 Nov 2026, 23:47 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Cash, fiscal 2025
$322.93M
Change on fiscal 2024
+2.4%
Highest on record
$386.19Mfiscal 2023
Lowest on record
$200.84Mfiscal 2022
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Axsome Therapeutics cash on hand, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $386.19M in fiscal 2023 and the lowest $200.84M in fiscal 2022.

History · 4 fiscal years

Cash by fiscal year

Axsome Therapeutics cash on hand, year by year

Axsome Therapeutics (AXSM) cash on hand by fiscal year
Fiscal yearCashChangeYear ended
2025$322.93M 2.4% up
2024$315.35M 18.3% down
2023$386.19M 92.3% up
2022$200.84M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

How to read it

Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.

Cash at health care companies of similar size

Cash of Axsome Therapeutics and comparable companies
CompanyCashFiscal year
Immunovant IMVT$902.11M2026
Axsome Therapeutics AXSM$322.93M2025
Chemed CHE$74.52M2025
Oruka Therapeutics ORKA$337.04M2025
Arrowhead Pharmaceuticals ARWR$1.19B2026
MSA Safety MSA$165.07M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on AXSM

Axsome Therapeutics, figure by figure

Axsome Therapeutics (AXSM) overview: price, valuation and scorecardAll health care companies by market value

Axsome Therapeutics cash on hand: questions and answers

How much cash does Axsome Therapeutics have?

Axsome Therapeutics (AXSM) held cash of $322.93M at the end of fiscal 2025 (December 31, 2025). That is 2.4% higher than the $315.35M of fiscal 2024.

What are the highest and lowest cash figures on record for Axsome Therapeutics?

Across the 4 fiscal years on record (2022–2025), the highest was $386.19M in fiscal 2023 and the lowest $200.84M in fiscal 2022.

How is Axsome Therapeutics's cash calculated?

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Axsome Therapeutics (AXSM) cash on hand”, data as of 17 November 2026. https://funkfolio.com/stock/AXSM/cash

Underlying data: the company's filings with the SEC and Yahoo Finance.